Organisation paid for research Program year 2024 Source: CMS Open Payments

Id Care PA

Neither a doctor nor a teaching hospital

Research payments

$3,996,717

542 payments

Through program year 2024, Id Care PA is reported as receiving $3,996,717 in research payments, across 542 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $18,134 11
2023 Research $15,125 3
2022 Research $58,729 90
2021 Research $148,023 193
2020 Research $3,225,479 82
2019 Research $531,227 163

Breakdown

Who paid Research payments · program years 2019–2024
  1. Gilead Sciences, Inc. $3,063,611 79 payments
  2. Janssen Research & Development, LLC $360,020 104 payments
  3. Alkermes, Inc. $264,499 5 payments
  4. Pfizer Inc. $152,839 339 payments
  5. AbbVie, Inc. $136,445 3 payments
  6. GlaxoSmithKline, LLC. $18,134 11 payments
  7. Insmed, Inc. $1,170 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. The Simple Study in Coronavirus, Severe Subjects $1,622,920 1 payment
  2. The Simple Study in Coronavirus, Severe Subjects $657,080 1 payment
  3. The Simple Study in Coronavirus, Severe Subjects $482,624 1 payment
  4. Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care $264,499 5 payments
  5. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $152,839 339 payments
  6. A17-099 $136,445 3 payments
  7. A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection $129,481 31 payments
  8. A Phase 2b Multi Center Double-blind Active controlled Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ73763989 and/or JNJ56136379 for the Treatment of Chronic Hepatitis B Virus Infection $70,440 27 payments
  9. A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ 56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection $59,405 16 payments
  10. A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects $37,653 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record